Trial Profile
A Phase Ib/2 Clinical Study to Evaluate the Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of Fruquintinib Combined With Paclitaxel in Patients With Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hutchison MediPharma
- 21 Feb 2018 Status changed from active, no longer recruiting to completed.
- 23 Feb 2017 Planned End Date changed from 1 Feb 2017 to 31 Mar 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Mar 2017.